Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2608204 · 1 trial · 1 indication
Clinically significant adverse effects refer to any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the investigational product, whether or not related to the medicinal investigational product.
| Arm | Type | Description |
|---|---|---|
| LY2608204 | EXPERIMENTAL | Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment. |
| Name | Type | Description |
|---|---|---|
| LY2608204 | DRUG | Administered orally. |
Inclusion Criteria: * Patients diagnosed with Type 2 diabetes mellitus (T2DM) who are currently treated with diet/lifestyle measures alone or in combination with anti-diabetic agents, including insulins * Have fasting blood glucose (FBG) greater than or equal to 160 milligram/deciliter (mg/dL), wit...
LY2608204 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It has also been evaluated in healthy volunteers to compare different formulations. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
LY2608204 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting early-stage clinical trials to evaluate the safety and tolerability of this investigational compound.
LY2608204 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one in patients with Type 2 Diabetes and another in healthy volunteers. The drug remains investigational and has not received regulatory approval for any indication.
LY2608204 has been studied in two completed Phase 1 trials. NCT01247363 enrolled 20 patients with Type 2 Diabetes in the United States and Singapore. NCT01313286 enrolled 16 healthy volunteers in Singapore to compare two forms of the drug. Both trials are completed.
LY2608204 is the code name used by Eli Lilly for this investigational compound. No alternative brand names or other designations have been disclosed in the clinical trial information. The drug is identified solely by its LY2608204 designation in the studies.